Dallas-Fort Worth International Airport, TX's Revenue Bonds Rated 'A+' On Anticipated Capital Program Oct 10

  • ID: 2084132
  • October 2010
  • Region: Global
  • Standard & Poors
1 of 3

BOSTON (Standard & Poor's) Oct. 26, 2010--Standard & Poor's Ratings Services has assigned its 'A+' rating to Dallas-Fort Worth International Airport's (DFW) $301 million series 2010A joint revenue bonds. We also affirmed our 'A+' ratings on $3.5 billion of joint revenue bonds currently outstanding. The ratings are based on a our view of the airport's strong business position and key role within American Airlines' route network, solid financial performance against weakened traffic levels, and a financial plan associated with its large capital plan that results in a more highly leveraged facility with higher costs but still-solid margins. More specifically, the rating reflects the following fundamentals, which we view as credit strengths: A strong service area economy -- weakened by the...

Companies mentioned in this report are:
- Dallas Fort Worth Intl Arpt

Action: Affirmed
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Dallas Fort Worth Intl Arpt

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.